Editing HBM Healthcare Investments
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 575: | Line 575: | ||
'''Exhibit 16: Major shareholders'''<ref>Source: HBM Healthcare Investments, as at 31 March 2022.</ref> | '''Exhibit 16: Major shareholders'''<ref>Source: HBM Healthcare Investments, as at 31 March 2022.</ref> | ||
'''Exhibit 17: Average daily volume'''<ref>Source: Refinitiv. Note 12 months to 16 May 2022.</ref> | '''Exhibit 17: Average daily volume'''<ref>Source: Refinitiv. Note 12 months to 16 May 2022.</ref> | ||
[[File:Average daily volume.png| | [[File:Average daily volume.png|600px]] | ||
HBMN is structured as a closed-ended investment company with one class of share, listed on the SIX Swiss Exchange. It has 7.0m ordinary shares in issue, unchanged since the start of FY19. As shown in Exhibit 16, the fund is owned by a diverse range of shareholder types, with only one entity (Nogra Pharma Invest, which holds c 16% of the shares) having an interest of more than 3%. Exhibit 17 shows an average daily traded volume of 4,500 shares (0.06% of the share base) over the 12 months to 16 May 2022; this is down markedly from c 7,100 shares (c 0.10% of the share base) in the previous 12 months, reflecting a generally more difficult demand environment for healthcare investments, also shown in HBMN’s wider discount to NAV (see Exhibit 15). | HBMN is structured as a closed-ended investment company with one class of share, listed on the SIX Swiss Exchange. It has 7.0m ordinary shares in issue, unchanged since the start of FY19. As shown in Exhibit 16, the fund is owned by a diverse range of shareholder types, with only one entity (Nogra Pharma Invest, which holds c 16% of the shares) having an interest of more than 3%. Exhibit 17 shows an average daily traded volume of 4,500 shares (0.06% of the share base) over the 12 months to 16 May 2022; this is down markedly from c 7,100 shares (c 0.10% of the share base) in the previous 12 months, reflecting a generally more difficult demand environment for healthcare investments, also shown in HBMN’s wider discount to NAV (see Exhibit 15). |